XML 43 R28.htm IDEA: XBRL DOCUMENT v3.25.1
COLLABORATION AND LICENSING AGREEMENTS (Tables)
 3 Months Ended
Mar. 31, 2025
Collaboration and Licensing Agreements  
Schedule of Revenue
Disaggregation of total revenues by nature is as follows:
Three Months Ended March 31,
(in thousands)
20252024
Product sales, net
$67,814 $43,512 
Licensing revenue5,020 17 
Non-cash royalty revenue related to the sale of future royalties1,026 368 
Product supply revenue254 2,126 
Total revenues$74,114 $46,023 
Total product sales, net was as follows:
Three Months Ended March 31,
(in thousands)
20252024
Product sales, net
IBSRELA$44,403 $28,361 
XPHOZAH23,411 15,151 
Total product sales, net$67,814 $43,512 
The following table summarizes total revenues by collaboration partner:
Three Months Ended March 31,
(in thousands)20252024
Licensing revenue
Fosun Pharma
$5,000 $— 
Knight
20 17 
Total licensing revenue
$5,020 $17 
Product supply revenue  
Kyowa Kirin
— 2,126 
Knight
254 — 
Total supply revenue
$254 $2,126 
Non-cash royalty revenue related to the sale of future royalties  
Kyowa Kirin
$1,026 $368 
Schedule of Deferred Revenue Balances
The following table presents changes in our current and non-current deferred revenue balances, which are all attributable to Kyowa Kirin:
20252024
(in thousands)CurrentNon-CurrentCurrentNon-Current
Deferred revenue balance as of January 1,
$10,686$7,232$7,182$8,644
Prepaid product supply2271,1187323,459
Product supply delivered——(1,328)—
Deferred revenue balance as of March 31,$10,913$8,350$6,586$12,103